Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Clinical trial NCT00696072 · COMPLETED
Trial details
- NCT number
- NCT00696072
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-08-01
- Primary completion
- 2014-06-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.